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High incidence and poor prognosis of lung cancer make it a major health problem worldwide. Although 
smoking is a major cause of lung cancer, only some smokers develop lung cancer, which suggests that 
there is a genetic predisposition in some individuals. 8-OHG is an important oxidative base lesion and 
may elevate due to cancer and smoking. It is repaired by 8-hydroxyguanine DNA glycosylase 1 (OGG1), 
which has several polymorphisms. Although the Ser326Cys polymorphism is consistently associated with 
a range of cancers, findings about this polymorphism and lung cancer risk are contradictory. To date, 
no study has examined this association in the Turkish population. We conducted a case-control study to 
investigate the association between OGG1 Ser326Cys polymorphism and the risk of lung cancer using 
PCR-RFLP. We also evaluated gene-smoking interaction and excretion of urinary 8-OHdG. Our results 
suggest that the OGG1 Ser326Cys polymorphism is not a genetic risk factor for lung cancer, and that the 
heterozygous genotype is associated with a significantly reduced risk for lung cancer. The levels of 8-OHdG 
did not correlate with the polymorphism and smoking. Larger association studies are needed to validate 
our findings, and mechanistic studies are needed to elucidate the underlying molecular mechanisms of 
this association.
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High incidence and poor prognosis of lung cancer 
make it a major health problem worldwide (1, 2). Lung 
cancer, which was initially considered an epidemic 
disease among men in industrialised nations, has now 
become the leading killer cancer in both sexes in the 
United States and an increasingly common disease 
of both sexes in developing countries (3).
In the Turkish population, it is the most common 
cancer in men and the sixth most common in women. 
Its incidence is 14.19 per 100,000 men and 1.24 
per 100,000 women (4). While more than 80 % of 
people who develop lung cancer are current or former 
smokers, only a small portion of smokers develop 
lung cancer, which suggests that there is a genetic 
predisposition in some individuals. To better understand 
the aetiology of this disease and more effectively target 
high-risk individuals in prevention and screening, it is 
important to identify factors that influence a smoker’s 
risk of developing lung cancer (5).
Tobacco smoking which is the major cause of lung 
cancer, increases the rate of oxidative DNA damage 
(6), and tobacco smoke contains multiple carcinogens 
z
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and reactive oxygen species (ROS) that are known 
to chemically modify DNA and lead to mutations. 
Accumulation of mutations in critical oncogenes and 
tumour suppressor genes promotes cancer (7, 8). 
Among many types of oxidative DNA damage, the 8-
hydroxyguanine (8-OHG) residue is one of the most 
abundant oxidative products of cellular DNA and is a 
mutagenic agent causing GC-to-TA transversions (9, 
10). Increase in 8-OHG DNA content has been shown 
to elevate the cancer risk (11). It can be repaired by 
the activity of 8-hydroxyguanine DNA glycosylase 1 
(OGG1), which catalyses the removal of 8-OHG by 
cleaving the N-glycosyl bonds between the oxidised 
guanine and the deoxyribose backbone, leaving an 
apurinic/apyrimidinic site as an intermediate product 
(12). Studies on genetic structure have revealed the 
presence of several polymorphisms within the OGG1 
locus (13). Among them, a C/G polymorphism at 
position 1245 in the 1α-specific exon 7 of the OGG1 
gene results in an amino acid substitution from serine 
to cysteine in codon 326 (14). It is not clear whether the 
amino acid substitution affects the catalytic properties 
of the enzyme, and limited knowledge is available on 
the association between cancer susceptibility and 
single nucleotide polymorphisms in this critical DNA 
repair gene (15, 16). In some studies, the OGG1 
polymorphism Ser326Cys has been associated with 
increased risk of lung cancer. On the other hand, 
contradictory results have been reported about the 
association of the OGG1 Ser326Cys polymorphism 
and lung cancer risk for different populations. So far, 
however, there no such association has been studied 
in the Turkish population (17-22).
Among biomarkers used to identify cancer risk 
factors, p53 tumour suppressor gene mutations 
have been determined in several human cancers 
(23). It is well known that more than 50 % of lung 
cancers carry a p53 mutation. The most common 
type of p53 mutation is the guanine (G) to thymine
(T) transversion (24), like OGG1. Furthermore, there 
are several distinct regions of frequent allele loss on 
chromosome 3p, indicating the presence of multiple 
tumour suppressor genes, including p53. Therefore, 
the OGG1 gene, located at 3p25 can be a strong 
tumor suppressor gene candidate (23) and partial 
or total loss of the mammalian Ogg1 proteins may 
predispose cells toward oncogenic transformation 
(25).
In our case-control study of the Turkish population, 
we wanted to see whether OGG1 Ser326Cys 
polymorphism was associated with susceptibility 
to lung cancer. Furthermore, gene-smoking status 
analyses were conducted to establish the gene-
environment interaction between OGG1 Ser326Cys 
polymorphism and cumulative cigarette smoking in 
lung cancer. We also evaluated urinary 8-hydroxy-2’-
deoxyguanosine (8-OHdG) as a marker of cellular 
oxidative stress in lung cancer patients who did not 
receive any radiotherapy and/or chemotherapy and in 
control subjects. We investigated whether there was 




We conducted a molecular epidemiologic case-
control study that included 165 lung cancer patients 
(20 women and 145 men) and 250 control subjects 
(83 women, and 167 men). The age of control subjects 
ranged from 20 to 82 years (53.2±0.75) and in lung 
cancer patients from 18 to 82 years (56.99±0.79). 
Details are given in Table 1.
The lung cancer patients were from hospital-
based, case-control studies of lung cancer carried out 
in Turkey. They were recruited at two hospitals, and 
the study was approved by the ethical committee of 
the Ankara Numune and Ankara Oncology Education 
and Research Hospitals. According to histological sub-
types, lung cancer patients were classified as small cell 
lung cancer (SCLC, n=38) and non-small cell lung 
cancer (NSCLC, n=120). In general, the prevalence 
of NSCLC is significantly higher than the prevalence of 
SCLC. All cancer diagnoses (except for seven patients) 
were confirmed by histopathology and cytology. The 
histopathologic type was determined using the World 
Health Organization (WHO) lung tumour classification 
in clinical use during patient accrual.
We asked the subjects to fill out a self-administered 
questionnaire that included general characteristics 
(age, sex, and socio-demographic characteristics), 
personal and family medical history, and smoking and 
drinking habits. Smoking was much more prevalent 
among lung cancer patients (85.5 %) than in control 
subjects (50.4 %). All study participants signed an 
informed consent form and completed a detailed 
questionnaire about smoking habits.
Sample collection
Five millilitres of peripheral blood was collected 
in a sterile EDTA container (Sigma) via venipuncture 
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from each control subject and patient to determine 
OGG1 Ser326Cys polymorphism by PCR-RFLP. To 
detect urinary 8-OHdG levels 5-mL spot urine samples 
were collected from 72 of 165 patients who had never 
received any chemotherapy and/or radiotherapy and 
from 61 of 250 control subjects. We could collect 
urine samples from only 80 controls and the sixty-
one were age- and sex-matched to lung cancer 
patients. All blood and urine samples were stored at 
-20 °C until analysis.
DNA isolation and determination of OGG1 
genotype
DNA was extracted from whole blood using a 
sodium perchlorate / chloroform extraction method 
(9). We used a simple PCR-RFLP method (9) to 
identify the Ser326Cys variant, because the C to G 
transversion creates a new Fnu4HI restriction site. 
Briefly, the 207 bp fragment was amplified by PCR in a 
30 µL reaction volume that contained 100 ng genomic 
DNA, 0.2 mmol L-1 of dNTP (Fermentas Life Sciences, 
Lithuania), 1.5 mmol L-1 of MgCl2 (Fermentas Life 
Sciences, Lithuania), 0.3 pmol of each primer and 1 
unit of Taq DNA polymerase (Fermentas Life Sciences, 
Lithuania). The primers used for amplification of 
OGG1 gene exon 7, containing Ser326Cys, were 
5’-ACT GTC ACT AGT CTC ACC AG-3’ forward 
(Iontek)and 5’-TGA ATT CGG AAG GTG CTT GGG 
GAA T-3’ reverse(Iontek). Cycling conditions were as 
follows: initial denaturation at 94 °C for 2 min, then 
amplification by 33 cycles of denaturation at 94 °C 
for 15 s, annealing at 60 °C for 30 s, and elongation 
at 72 °C for 35 s, followed by extension at 72 °C for 
10 min. The PCR product was digested with 3 units 
of Fnu4H1 (Fermentas, Lithuania) at 37 °C for 16 h, 
and then electrophoresed on a 6 % polyacrylamide 
gel (Applichem). The Cys/Cys homozygote is cleaved 
by Fnu4HI, and yields 2 bands (100 bp and 107 bp 
bands). The Ser/Ser homozygote is not cleaved by 
FNU4HI, and the single 207 bp band remains. The 
Ser/Cys heterozygote contains all 3 bands (100 bp, 
107 bp, and 207 bp bands) following restriction 
digestion (26). Negative controls (no template) and 
positive controls were included in all sets.
Detection of urinary 8-OHdG levels
Stressgen’s StressXpress DNA Damage ELISA 
(enzyme-linked immunosorbent assay) (Stressgen 
Bioreagents) is a fast and sensitive competitive 
immunoassay for the detection and quantitation of 
8-OHdG in spot urine samples. Measurement of 
urinary 8-OHdG is useful as an indicator of oxidative 
damage. Urine samples were diluted with sample 
diluents. We determined the optimal sample dilutions 
for our particular experiments to avoid being out of 
the range of the standard curve. Fifty microlitres of 
each prepared standard and samples were added to 
the wells of 8-OHdG immunoassay plate in duplicates, 
and then 50 µL of diluted anti-8-OHdG was added 
into each well, except for the blank. The plate was 
Table 1 General characteristics of lung cancer patients and controls 
Controls Patients p SCLC NSCLC p





Women / N (%) 83 (33.2) 20 (12.1) 6 (15.8) 14 (11.7)
Men / N (%) 167 (66.8) 145 (87.9) 32 (84.2) 106 (88.3)




Never 121 (48.4) 24 (14.5) 5 (13.2) 19 (15.8)





80 (62) 70 (49.6) 20 (60.6) 47 (46.5)
>20 cigarettes 
per day
26 (20.2) 64 (45.4) 13 (39.4) 48 (47.5)
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incubated at room temperature for one hour, and the 
wells were washed using the wash buffer, and 100 µL 
of diluted anti-Mouse IgG:HRP conjugate was added 
to each well, except for the blank. Again, the plate 
was incubated at room temperature for one hour, 
and the wells were washed using the wash buffer. One 
hundred microlitres of TMB substrate were added 
into each well and the plate was incubated at room 
temperature for 15 min in the dark. After adding 
100 µL acid stop solution into each well, absorbance 
was measured at 450 nm. The standard curve was in 
the range of 0.94 ng mL-1 to 60 ng mL-1. The 8-OHdG 
calibration curve was plotted and 8-OHdG sample 
concentration was calculated. Urinary 8-OHdGper 
creatinine levels were expressed after correction for 
creatinine concentrations and presented as nmol per 
mmol creatinine.
Statistical Analyses
Data analysis was performed using SPSS for 
Windows, version 11.5. Shapiro-Wilk test was used in 
order to detect whether the continuous variables were 
normally distributed or not. Descriptive statistics were 
shown as mean ± standard error for continuous data. 
The differences regarding continuous variables were 
evaluated using the Mann-Whitney U test or Kruskal-
Wallis, according to the number of independent groups. 
When the p-value from the Kruskal-Wallis test was 
statistically significant, we applied the Kruskal Wallis 
multiple comparison tests to see which groups differed 
from which. Categorical comparisons were evaluated 
using the chi-square or Fisher’s exact test, where 
applicable. Multiple logistic regression analysis was 
adjusted for age, sex, BMI, and smoking status. Odds 
ratio and 95 %CIs for each independent variable were 
calculated. The Bonferroni correction was applied for 
all possible within-group comparisons. A p value of less 
than 0.05 was considered statistically significant.
RESULTS
We tested the association between OGG1 
Ser326Cys polymorphism and the risk of lung cancer 
in a population-based, case control study of 165 cases 
and 250 controls in the Turkish population. Among 
the lung cancer patients, 23 % (n=38) were diagnosed 
SCLC, 72.7 % (n=120) NSCLC, and the remaining 
7.2 % (n=7) were of unknown histological type. The 
subtypes of NSCLC were adenocarcinoma (25 %), 
squamous cell carcinoma (34.2 %), and 40.8 % was 
unknown.
The allele frequency of the variant G allele for 
OGG1 Ser326Cys was 0.28 for the lung cancer 
patients and 0.33 for controls. The prevalence of 
this polymorphism followed the Hardy-Weinberg 
equilibrium. The frequency distributions of alleles for 
OGG1 are shown in Table 2. To determine whether the 
OGG1 326Cys allele contributed to the increased risk 
of lung cancer, we compared the prevalence of OGG1 
alleles in lung cancer patients and control subjects. 
The more common allele 326Ser was considered 
the reference genotype, whereas the less common 
allele 326Cys was examined as the variant. ORs 
were adjusted for age, sex, BMI, and smoking status. 
There was no association between the polymorphism 
in OGG1 Ser326Cys and the risk of lung cancer 
(OGG1 Ser326Cys ORadj=0.87; 95 % CI=0.551-1.36; 
p=0.531 and OGG1 Cys326Cys ORadj=0.59; 95 % 
CI=0.283-1.235; p=0.162).
The contribution of the OGG1 Ser326Cys 
polymorphism in each histological sub-type is shown 
in Table 3. To assess whether OGG1 Ser326Cys 
polymorphism was associated with histological 
sub-types of the lung cancer, cases were stratified 
according to tumour histological classification. When 
stratified by histology, a significant decrease in risk 
was observed in SCLC sub-group for Ser326Cys 
genotype. However, it was no longer significant when 
the groups were adjusted for age, sex, and smoking. 
No association was observed between NSCLC and 
the OGG1 Ser326Cys polymorphism. The OGG1 
polymorphism did not significantly alter lung cancer 
risk by sex (p<0.05 in the crude and adjusted 
analysis). This suggests that sex is not the confounder 
of lung cancer risk.












Ser/Ser 115 (46) 86 (52.1) 1 1
Ser/Cys 106 (42.4) 65 (39.4) 0.82 (0.541-1.244) 0.35 0.87 (0.551-1.36) 0.531
Cys/Cys 29 (11.6) 14 (8.5) 0.65 (0.322-1.295) 0.218 0.59 (0.283-1.235) 0.162
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The analysis of potential interaction between the 
OGG1 polymorphism and cigarette smoking on the 
risk of lung cancer (Table 4) showed no association 
between the OGG1 Ser326Cys polymorphism 
and lung cancer risk regarding to smoking status. 
Furthermore, variant genotypes were not individual 
risk factors in light smokers (<20 cigarettes per day). 
On the other hand, OGG1 variant genotypes were 
inversely associated with the risk of lung cancer in 
subjects who smoked more than 20 cigarettes per 
day, suggesting the protective effect of the genotype 
in heavy smokers. 
We also measured the levels of urinary 8-OHdG 
as a biomarker of oxidative DNA damage in urine 
samples from 72 lung cancer patients (13 women, 
59 men) who did not receive any chemotherapy and 
radiotherapy as well as in 61 (age and sex matched) 
control subjects (17 women, 44 men). The mean 
age of lung cancer patients and controls did not 
significantly differ (mean ± SEM; 56.50±1.30 years 
vs. 54.84±1.38 years, p>0.05). Mean BMI of the 
control subjects was higher than in the lung cancer 
patients (p<0.05).
Table 5 shows the levels of urinary 8-OHdG in lung 
cancer and control subjects according to sex, age, 
smoking status, and histological sub-types. There 
was no significant difference in the levels of urinary 
8-OHdG between the lung cancer patients and control 
subjects. Neither sex nor age contributed (the subjects 
were grouped by age; ≤60 and >60 years) to the 
levels of urinary 8-OHdG levels in either lung cancer 
patients or controls. Our data showed that smoking 
















Ser/Ser 115 (46) 25 (65.8) 1 1
Ser/Cys 106 (42.4) 10 (26.3) 0.43 (0.199-0.946) 0.036* 0.56 (0.232-1.331) 0.188
Cys/Cys 29 (11.6) 3 (7.9) 0.48 (0.134-1.686) 0.25 0.55 (0.145-2.078) 0.378
NSCLC
(n=120)
Ser/Ser 115 (46) 59 (49.2) 1 1
Ser/Cys 106 (42.4) 50 (41.7) 0.92 (0.580-1.456) 0.72 1.01 (0.602-1.683) 0.980
Cys/Cys 29 (11.6) 11 (9.2) 0.74 (0.345-1.584) 0.437 0.68 (0.299-1.542) 0.355
Sex
Women
Ser/Ser 37 (44.6) 10 (50) 1 1
Ser/Cys 36(43.4) 9 (45) 0.93 (0.337-2.541) 0.880 0.92 (0.335-2.548) 0.878
Cys/Cys 10 (12) 1(5) 0.37 (0.42-3.244) 0.369 0.37 (0.042-3.269) 0.371
Men
Ser/Ser 78 (46.7) 76 (52.4) 1 1
Ser/Cys 70 (41.9) 56 (38.6) 0.82 (0.512-1.317) 0.413 0.84 (0.503-1.404) 0.507
Cys/Cys 19 (11.4) 13 (9) 0.70 (0.324-1.521) 0.370 0.65 (0.288-1.474) 0.304
Table 4 Association between the OGG1 Ser326Cys polymorphisms and lung cancer risk according to smoking status
Genotype









Ser/Ser 55 (45.5) 12 (50) 1  1  
Ser/Cys 55 (45.5) 11 (45.8) 0.92 (0.373-2.253) 0.85 0.87 (0.349-2.166) 0.764
Cys/Cys 11 (9) 1 (4.2) 0.42 (0.049-3.542) 0.423 0.41 (0.048-3.55) 0.419
Smoker
Ser/Ser 59 (46.8) 74 (52.5) 1  1  
Ser/Cys 49 (38.9) 54 (38.3) 0.88 (0.524-1.472) 0.623 0.84 (0.487-1.464) 0.547





Ser/Ser 37 (46.3) 33 (47.1) 1  1  
Ser/Cys 33 (41.2) 32 (45.7) 1.09 (0.553-2.137) 0.808 1.11 (0.543-2.266) 0.777




Ser/Ser 9 (34.6) 38 (59.4) 1  1  
Ser/Cys 11 (42.3) 18 (28.1) 0.39 (0.136-1.101) 0.075 0.30 (0.095-0.939) 0.039*
Cys/Cys 6 (23.1) 8 (12.5) 0.32 (0.87-1.140) 0.078 0.22 (0.055-0.915) 0.037*
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had no effect on the levels of urinary 8-OHdG in 
either group (p>0.05). Furthermore, control 8-OHdG 
levels did not significantly differ from those in SCLC 
or NSCLC patients. 
In this study, we further investigated the association 
between urinary 8-OHdG levels and OGG1 Ser326Cys 
polymorphism (Table 6) and found that the excretion of 
8-OHdG was not associated with the OGG1 Ser326Cys 
polymorphism. In lung cancer patients, there was no 
effect of the OGG1 Ser326Cys polymorphism on the 
levels of urinary 8-OHdG. On the other hand, in the 
control subjects, urinary 8-OHdG levels of subjects 
with the Ser326Ser genotype were found to be higher 
than in subjects with the Ser326Cys (p=0.006) and 
Cys326Cys (p=0.008) genotypes. However, no 
difference was observed between variant genotypes 
(p=0.179). Our data demonstrated that the urinary 
8-OHdG excretion was not affected by the OGG1 
Ser326Cys polymorphism in respect to smoking.
Table 5 The effect of 8-OHdG excretion (nmol mmol-1 of creatinine) according to demographic characteristics 
Groups


















Men: 44 71.80±8.83 59 67.34±6.26 0.920
Age













Former 15 77.32±11.33 29 69.52±8.65 0.480
Current 11 79.90±24.43 25 65.06±10.99 0.919
Histological
sub-types
SCLC 61 70.03±7.11 10 89.05±15.97
0.124
0.173
NSCLC 61 70.03±7.11 61 63.93±6.04 0.619
p**: Statistical analysis between lung cancer patients and controls



















Ser/Cys 31 59.50±9.28 24 67.01±8.14 0.186









Ser/Cys 15 49.96±9.78 5 70.73±14.92 0.197







Ser/Cys 10 76.49±15.08 12 69.70±13.52 0.674







Ser/Cys 6 55.03±34.23 7 59.74±13.35 0.101
Cys/Cys 0 0 4 71.67±38.16  
n# : no genotype data for 8 lung cancer subjects
p**: statistical analysis between lung cancer patients and controls
•: not significant according to Bonferroni correction(p>0.025)
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DISCUSSION
Oxidative DNA damage is believed to be implicated 
in lung carcinogenesis. The potential mechanism of 
carcinogenesis in the lung tissue may involve tissue 
damage and regeneration in the presence of a high 
ROS release from inflammatory cells that can interact 
with DNA in epithelial cells to produce permanent 
genomic mutations (27). One of them, 8-OHG is a 
mutagenic and most common oxidative modification 
of guanine, and has a pivotal role in the development 
of lung cancer. Base excision repair (BER) is a highly 
conserved essential mechanism for maintaining 
genome integrity. Impaired BER function can give rise 
to the accumulation of 8-OHG lesion and other DNA 
base lesions, which may influence the initiation and 
progression of cancer (28). OGG1 is a key enzyme in 
short-patch BER because it recognises and performs 
initial excision of the most common form of oxidative 
DNA base damage, 8-OHG (29). OGG1 encodes an 
8-oxoguanine DNA glycosylase/AP lyase that catalyzes 
the removal of 8-OHG from DNA (30). There are 
many polymorphisms found in the OGG1 gene. The 
most studied is the single nucleotide polymorphism at 
codon 326 (Ser326Cys). Homozygous carriers of the 
variant form of the OGG1 Ser326Cys gene appear to 
have reduced repair capacity for oxidised DNA lesions 
(31, 32), but this association has not been found in 
all investigations (33).
Epidemiological studies of the OGG1 Ser326Cys 
polymorphism in relation to cancer have yielded mixed 
results with a weak association between the OGG1 
Ser326Cys genotype and the risk of lung cancer (18, 
33-35). Since there have been contradictory findings 
so far, we conducted a case-control study of 165 
lung cancer cases and 250 controls using PCR-RFLP 
method to identify the Ser326Cys and a questionnaire 
approach to investigate its association with lung 
cancer risk and possible interaction with smoking. We 
found that the distribution of the OGG1 Ser326Cys 
genotypes in controls (Ser/Ser, 46.0 %; Ser/Cys, 
42.4 %; and Cys/Cys 11.6 %) did not significantly 
differ from lung cancer patients (52.1 %, 39.4 %, 
and 8.5 %, respectively) (p>0.05). No statistically 
significant associations between the OGG1 Ser326Cys 
polymorphism and lung cancer risk were observed. 
Our results are similar to Wikman et al. and some 
other authors (19, 36-38). Wikman et al. carried out 
a case-control study to investigate the association 
between the OGG1 Ser326Cys polymorphism and the 
risk of lung cancer. They found no major difference in 
Ser326Cys genotype distribution between lung cancer 
patients and controls and suggested the studied 
hOGG1 polymorphisms were probably not major 
contributors to individual lung cancer susceptibility in 
Caucasians (19). Hung et al. also observed that there 
were no such associations between them (36, 37).
Sorensen et al. examined the associations between 
polymorphism and the intake of fruits and vegetables 
and smoking in the development of lung cancer in 431 
lung cancer patients and 796 controls. They found no 
overall association between the OGG1 polymorphism 
and lung cancer (38). Vogel et al. did not find any 
association between the polymorphisms OGG1 
Ser326Cys and the risk of lung cancer (37). Sugimura 
et al. found that the Ser326Cys polymorphism 
was not associated with an increased risk of lung 
cancer in any subtypes; however, when homozygous 
Cys326Cys were compared with other genotypes in 
combination, an increased risk was observed for the 
squamous cell carcinoma and nonadenocarcinoma 
after adjustment for age and smoking (17). On the 
other hand, Ito et al. did not find any effects of the 
OGG1 Ser326Cys polymorphism on the development 
of either adenocarcinomas or small cell carcinoma 
(39). In our study, we found a significant decrease in 
the risk of SCLC for the Ser326Cys genotype, but this 
significance disappeared after adjusting for age, sex, 
and smoking. A reduced cancer risk associated with 
the OGG1 Ser326Cys polymorphism, as found in our 
study, has previously been reported by De Ruyck et al. 
(22). We believe that this may be due to an adaptive 
response with alternative pathyways. Thus, proteins 
that play an important role in other repair pathways 
(NER), especially NEIL1 and MUTYH proteins, 
may be involved in the repair and prevention of 8-
oxodG-derived mutations and may be up-regulated 
by oxidative stress in subjects with the Ser326Cys 
polymorphism. Furthermore, NEIL1 is able to excise 
lesions where OGG1 has very limited activity.
We could not find any modifying effect of smoking 
combined with the OGG1 Ser326Cys polymorphism 
that may contribute to lung cancer development. The 
OR for smoking was not statistically different across 
the genotypes, but the sample size was too small 
to detect even a moderate interaction. Our results 
corroborate the findings by Ito et al. (39). Additional 
studies, especially on mRNA expression levels, need 
to be conducted to confirm this association.
In this study, there was no difference between lung 
cancer patients and control subjects in the levels of 
urinary 8-OHdG. Our results are similar to Loft et 
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al. (40) and Erhola et al.(41). Increased 8-OHdG 
excretion in controls indicates that their repair capacity 
is more effective than in the lung cancer patients.
Accumulating evidence seems to support 
the association between the OGG1 Ser326Cys 
polymorphism and smoking-related cancers, but 
the small sample size in our study and the presence 
of many conflicting data call for further studies 
on the association between the OGG1 Ser326Cys 
polymorphism and lung cancer, especially for studies 
that would include the smoking status in different 
populations with larger sample sizes. In conclusion, 
the OGG1 Ser326Cys polymorphism cannot explain 
individual variation in lung cancer susceptibility in 
humans. Future studies that investigate the mRNA 
expression, the activity of OGG1 protein, DNA repair 
capacity and excretion of DNA repair products are 
required to better understand the role of DNA damage 
in lung cancer.
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Sa`etak
POVEZANOST OGG1 Ser326Cys POLIMORFIZMA I RAZINA 8-OHdG U MOKRA]I SA SKLONOSTI 
OBOLIJEVANJU OD KARCINOMA PLU]A: REZULTATI ISPITIVANJA NA BOLESNICIMA I KONTROLNOJ 
POPULACIJI U TURSKOJ
Karcinom plu}a velik je javnozdravstveni problem u ~itavom svijetu zbog svoje visoke u~estalosti i lo{e 
prognoze. Premda je navika pu{enja jedan od glavnih uzro~nika karcinoma plu}a, od ove bolesti oboli 
samo dio populacije pu{a~a, {to govori u prilog postojanju genetske predispozicije za njezin nastanak. 
8-OHG je oksidativno o{te}enje baze u molekuli DNA ~ija se u~estalost mo`e pove}ati zbog zlo}udnih 
tumora i pu{enja. U popravku tog o{te}enja sudjeluje enzim 8-hidroksigvanin DNA-glikozilaza (OGG1) za 
koji je dokazano postojanje polimorfizma. Iako se polimorfizam Ser326Cys ~esto dovodi u vezu s razli~itim 
vrstama zlo}udnih bolesti, dosada{nji su rezultati o vezi izme|u polimorfizma tog enzima i rizika od pojave 
karcinoma plu}a kontradiktorni. Do danas na turskoj populaciji nisu provedena istra`ivanja koja bi dala 
jasne odgovore o toj povezanosti. Ovo je istra`ivanje usporedo provedeno u bolesnika i u zdravoj populaciji 
primjenom metode PCR-RFLP s ciljem utvr|ivanja mogu}e povezanosti polimorfizma OGG1 Ser326Cys 
i rizika od karcinoma plu}a. Nadalje, istra`ena je interakcija gena i navike pu{enja te ekskrecija 8-OHdG 
u mokra}i. Dobiveni rezultati pokazuju da polimorfizam OGG1 Ser326Cys nije genetski ~imbenik rizika 
od pojave karcinoma plu}a, a pokazalo se da je heterozigotni genotip povezan sa zna~ajno ni`im rizikom 
od karcinoma plu}a. Razine 8-OHdG izmjerene u mokra}i nisu bile u korelaciji ni s polimorfizmom ni 
s navikom pu{enja. Zaklju~ujemo da su za vrednovanje dobivenih rezultata potrebna istra`ivanja na jo{ 
ve}em broju ispitanika te mehanisti~ka istra`ivanja koja bi mogla razjasniti molekularne mehanizme koji 
su u pozadini ove povezanosti.
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